Pacer Advisors
RCUS icon

Pacer Advisors’s Arcus Biosciences RCUS Stock Holding History

Pacer Advisors’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-545
Closed -$8.3K – 2668
2024
Q2 		$8.3K Sell
545
-1,034
-65% -$16.7K ﹤0.01% 3581
2024
Q1 		$29.8K Buy
+1,579
New +$27.3K ﹤0.01% 3359
2021
Q2 		– Sell
-2,145
Closed -$60K – 1529
2021
Q1 		$60K Buy
2,145
+66
+3% +$2.3K ﹤0.01% 1419
2020
Q4 		$54K Buy
2,079
+338
+19% +$8.18K ﹤0.01% 1410
2020
Q3 		$30K Buy
+1,741
New +$38.9K ﹤0.01% 1335

Other funds holding RCUS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Pacer Advisors's RCUS Position: Q3 2024 in Review

Pacer Advisors sold out of Arcus Biosciences (RCUS) in Q3 2024, closing a stake of 545 shares — an estimated $8.3K sold.

Pacer Advisors first reported a position in RCUS in Q3 2020 and held it in 5 quarters. The position peaked at $60K in Q1 2021. 187 funds tracked by Wall St. Rank hold RCUS as of Q3 2024.

  • Pacer Advisors reported no remaining Arcus Biosciences position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 545 Arcus Biosciences shares in Q3 2024, an estimated $8.3K.
  • Pacer Advisors first reported a position in Arcus Biosciences in Q3 2020 and held it in 5 quarters.
  • Pacer Advisors's Arcus Biosciences position peaked at $60K in Q1 2021.
  • 187 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.